Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Anemia, Refractory, with Excess of Blasts × ruxolitinib × 30 days × Clear all

Sponsor

Conditions

Primary Myelofibrosis 4 Thrombocythemia, Essential 3 Myeloproliferative Disorders 3 Leukemia, Myeloid, Acute 3 Recurrence 2 Polycythemia Vera 2 Myelodysplastic Syndromes 2 Leukemia 2 Thalassemia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Myelodysplastic-Myeloproliferative Diseases 1 Lymphoma 1 Leukemia, Monocytic, Acute 1 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Graft vs Host Disease 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine phosphate 3 Azacitidine 3 venetoclax 2 fludarabine 2 Vorinostat 2 Specimen Handling 2 Mycophenolic Acid 2 Cyclophosphamide 2 Biopsy 2 decitabine and cedazuridine drug combination 1 cedazuridine 1 Whole-Body Irradiation 1 TAK-243 1 Stem Cell Transplantation 1 Mesna 1 Melphalan 1 Lenalidomide 1 Filgrastim 1 Cyclosporins 1 Cyclosporine 1 Clofarabine 1 Busulfan 1 Bone Marrow Transplantation 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡